IGEN International Inc.

Chemie/Biotech, AG

Angaben zur Organisation
IGEN BIOTECH GROUP has established a pipeline of microbiome modulators in clinical phase development that impact in the prevention and treatment of diseases known to be linked at human microbiome dysfunction such as cancer, neurodegenerative and metabolic diseases. IGEN BIOTECH GROUP R&D facilities include technical areas of In vitro cultivation and testing of microorganisms, mass spectrometry-based proteomics technologies to identify, characterize and quantify target proteins in various biological and biomedical samples, metabolomics for detection and quantification of small molecules (metabolites) in biological materials, microbiomics focusing on using molecular DNA microarray technology to address the complexities of human environmental microbiome ecology.